10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2017 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 27, 2018) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
| Cash Flows from Operating Activities | |||
| Net income | $ 2,418 | 3,941 | 4,459 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 4,637 | 5,441 | 6,375 |
| Intangible asset impairment charges | 646 | 3,948 | 162 |
| Provisional charge for one-time transition tax related to the enactment of U.S. tax legislation | 5,347 | 0 | 0 |
| Charge for future payments related to AstraZeneca collaboration license options | 500 | 0 | 0 |
| Charge related to the settlement of worldwide Keytruda patent litigation | 0 | 625 | 0 |
| Foreign currency devaluation related to Venezuela | 0 | 0 | 876 |
| Net charge related to the settlement of Vioxx shareholder class action litigation | 0 | 0 | 680 |
| Equity income from affiliates | (42) | (86) | (205) |
| Dividends and distributions from equity method affiliates | 2 | 16 | 50 |
| Deferred income taxes | (2,621) | (1,521) | (764) |
| Share-based compensation | 312 | 300 | 299 |
| Other | 269 | 313 | 874 |
| Net changes in assets and liabilities: | |||
| Accounts receivable | 297 | (619) | (480) |
| Inventories | (145) | 206 | 805 |
| Trade accounts payable | 254 | 278 | (37) |
| Accrued and other current liabilities | (922) | (2,018) | (8) |
| Income taxes payable | (3,291) | 124 | (266) |
| Noncurrent liabilities | (123) | (809) | (277) |
| Other | (1,091) | 237 | (5) |
| Net Cash Provided by Operating Activities | 6,447 | 10,376 | 12,538 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (1,888) | (1,614) | (1,283) |
| Purchases of securities and other investments | (10,739) | (15,651) | (16,681) |
| Proceeds from sales of securities and other investments | 15,664 | 14,353 | 20,413 |
| Acquisition of Cubist Pharmaceuticals, Inc., net of cash acquired | 0 | 0 | (7,598) |
| Acquisitions of other businesses, net of cash acquired | (396) | (780) | (146) |
| Dispositions of businesses, net of cash divested | 0 | 0 | 316 |
| Other | 38 | 482 | 221 |
| Net Cash Provided by (Used in) Investing Activities | 2,679 | (3,210) | (4,758) |
| Cash Flows from Financing Activities | |||
| Net change in short-term borrowings | (26) | 0 | (1,540) |
| Payments on debt | (1,103) | (2,386) | (2,906) |
| Proceeds from issuance of debt | 0 | 1,079 | 7,938 |
| Purchases of treasury stock | (4,014) | (3,434) | (4,186) |
| Dividends paid to stockholders | (5,167) | (5,124) | (5,117) |
| Proceeds from exercise of stock options | 499 | 939 | 485 |
| Other | (195) | (118) | (61) |
| Net Cash Used in Financing Activities | (10,006) | (9,044) | (5,387) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 457 | (131) | (1,310) |
| Net (Decrease) Increase in Cash and Cash Equivalents | (423) | (2,009) | 1,083 |
| Cash and Cash Equivalents at Beginning of Year | 6,515 | 8,524 | |
| Cash and Cash Equivalents at End of Year | 6,092 | 6,515 | 8,524 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2017 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |